French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
NCT ID: NCT01192347
Last Updated: 2021-06-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
177 participants
OBSERVATIONAL
2010-09-13
2012-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
NCT01352585
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
NCT04225156
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
NCT00202644
Anagrelide Retard in Essential Thrombocythemia
NCT02076815
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
NCT03102593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. High-risk ET Patients, uncontrolled by first-line (or previous) cytoreductive treatment for efficacy or tolerance reasons.
3. Patients who have been on second- or third-line XAGRID treatment for up to 1 month, or for whom a decision has been documented to commence second line XAGRID treatment.
4. Patients able to understand and able and willing to participate in the study, and provide a personally dated and signed written informed consent form.
Exclusion Criteria
2. Patients for whom there is an intention to treat with combinations of cytoreductive therapy.
3. Patients participating in a separate clinical trial where their treatment is defined by that study protocol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GH Pitie Salpetriere
Paris, Cedex 13, France
CH DU Pays D Aix
Aix-en-Provence, Cedex 1, France
Hopital Dupuytren
Limoges, Cedex 1, France
Hopital Emile Muller
Mulhouse, Cedex 1, France
Hopital Hotel Dieu Et Hme
Nantes, Cedex 1, France
Hopital Tenon
Paris, Cedex 20, France
Nouvelles Cliniques Nantaises
Nantes, Cedex 2, France
Hopital Hautepierre
Strasbourg, Cedex 2, France
Hopital De L Archet
Nice, Cedex 3, France
Clinique Du Parc
Caen, Cedex 4, France
Hotel Dieu
Angers, Cedex 9, France
CH Departemental Des Oudairies
La Roche-sur-Yon, Cedex 9, France
Hopital Pontchaillou
Rennes, Cedex 9, France
Hia Sainte Anne
Toulon, Cedex 9, France
Ch D Arras
Arras, Cedex, France
Hopital Robert Ballanger
Aulnay-sous-Bois, Cedex, France
CH De Blois
Blois, Cedex, France
Ch De Fleyriat
Bourg-en-Bresse, Cedex, France
CME
Brest, Cedex, France
Hopital Augustin Morvan
Brest, Cedex, France
Ch De Brive La Gaillarde
Brive-la-Gaillarde, Cedex, France
Hopital Henri Mondor
Créteil, Cedex, France
CH De Bicetre
Le Kremlin-Bicêtre, Cedex, France
CHRU Lille - Hopital Huriez
Lille, Cedex, France
Hopital Saint Philibert
Lomme, Cedex, France
Hopital Edouard Herriot
Lyon, Cedex, France
Institut J Paoli Calmettes
Marseille, Cedex, France
Hopital N D Bon Secours
Metz, Cedex, France
Clinique Pont de Chaume
Montauban, Cedex, France
Hopital Saint Antoine
Paris, Cedex, France
GH Pitie Salpetriere
Paris, Cedex, France
Hopital Saint Jean
Perpignan, Cedex, France
Hopital De Haut Leveque
Pessac, Cedex, France
CHI Poissy Saint German en Laye
Poissy, Cedex, France
Chi De Cornouaille
Quimper, Cedex, France
Hopital de La Maison Blanche
Reims, Cedex, France
Institut de Cancerologie de la Loire
Saint-Priest-en-Jarez, Cedex, France
Hopital Font Pre
Toulon, Cedex, France
Hopitaux de Brabois
Vandœuvre-lès-Nancy, Cedex, France
Ch De Vendome
Vendôme, Cedex, France
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, , France
Hopital Robert Boulin
Libourne, , France
CHU Nord - Chemin Des Bourrely
Marseille, , France
CHRA
Metz-Tessy, , France
Cabinet D'Hematologie
Perpignan, , France
Centre De Radiotherapie
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ; FOX study investigators. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. Eur J Haematol. 2014 Feb;92(2):127-36. doi: 10.1111/ejh.12210. Epub 2013 Nov 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPD422-702
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.